Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Aspartate beta-hydroxylase domain-containing protein 1 (ASPHD1)
- Target
- ASPHD1
- Molecular classification
- Enzyme (dioxygenase family)[1][2][5][6], Other (alpha-ketoglutarate-dependent dioxygenase-like)[1][2]
01
Overview
Aspartate beta-hydroxylase domain-containing protein 1 (ASPHD1) is a predicted enzyme of the alpha-ketoglutarate-dependent dioxygenase family, encoded by the ASPHD1 gene. It shares homology with aspartate beta-hydroxylase (ASPH) and is predicted to catalyze oxidative reactions involving aspartate or related substrates, although specific endogenous substrates remain unclear. ASPHD1 is expressed at low or undetectable levels in most normal tissues, but is upregulated in several cancers—including skin cutaneous melanoma—where higher expression is correlated with changes in immune signaling, tumor-infiltrating lymphocyte patterns, and patient prognosis. Current evidence supports its utility as a potential biomarker in cancer (especially melanoma), but does not support its classification as a validated therapeutic target or direct drug receptor[1][2][5][6].
- Other names
- ASPHD1aspartate beta-hydroxylase domain containing 1aspartate beta-hydroxylase domain-containing protein 1
02
Mechanism of action
No direct mechanism of action established for drugs targeting ASPHD1
03
Biological functions
Predicted dioxygenase activity (oxidative modification of substrates)[1][2][5][6]Regulation of epidermis development, skin development, and epidermal cell differentiation (inferred from gene enrichment in melanoma studies)[1]Implicated in control of tricarboxylic acid (TCA) cycle metabolites and chromatin modification (by analogy to close paralogs)[1]
04
Disease associations
Cancer (correlated with prognosis and progression in cutaneous melanoma/SKCM and several other identified cancers through expression analysis)[1]Neurodevelopmental/psychiatric diseases (schizophrenia 3, chromosome 16p11.2 deletion syndrome, spondylocostal dysostosis 5)[1][5]
05
Safety considerations
No specific safety concerns or therapeutic challenges reported, as this protein is *not currently a direct therapeutic target*
06
Interacting drugs
Doxorubicin (sensitivity changes with expression group in analyses, not direct interaction)[1]
2 more in the full profile.
07
Biomarkers
Potential prognostic biomarker in skin cutaneous melanoma (SKCM) based on expression level correlations with survival and immune microenvironment[1]
Beyond the preview
Go deeper on Aspartate beta-hydroxylase domain-containing protein 1 (ASPHD1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aspartate beta-hydroxylase domain-containing protein 1 (ASPHD1).